Effectiveness of CoronaVac primary series with and without booster against hospitalized COVID-19 during the omicron-predominant epidemic wave in the Philippines: a test-negative case-control study [0.03%]
新冠奥密克戎疫情期间中国国产疫苗冠状疫苗(CoronaVac)主系列及加强剂对菲律宾新冠住院患者的疗效：一种测试阴性病例对照研究
Kristal An Agrupis,Michelle Ylade,Yang Yang Qi et al.
Kristal An Agrupis et al.
Background: CoronaVac (Sinovac) was initially effective against symptomatic COVID-19 and severe outcomes, but its performance against the immune-evasive Omicron variant remains uncertain. This study evaluated the effectiv...
Public health impact of RSV vaccination among adults aged 60 years and older in the United States using real-world evidence from the initial post-introduction season [0.03%]
基于RSV疫苗上市初期季节的现实世界证据，美国老年人群中成人RSV疫苗接种的公共卫生影响
Frederik Verelst,David Singer,Jonathan Graham et al.
Frederik Verelst et al.
Background: Respiratory syncytial virus (RSV) is an important cause of severe respiratory illness in older adults and adults with certain health conditions. Adjuvanted RSVPreF3 and non-adjuvanted RSVpreF vaccines were app...
Public health impact of the adjuvanted RSVPreF3 vaccine in adults aged 60 years and older: results from a modeling study in six Latin America countries [0.03%]
用于60岁及以上成人的一种亚单位RSV候选疫苗的公共卫生影响：六个国家模型研究结果
Ru Han,Jorge A Gomez,Nancy Bellei et al.
Ru Han et al.
Background: Respiratory syncytial virus (RSV) can cause acute respiratory infection (ARI) and severe symptoms in older adults. The adjuvanted RSV prefusion F protein vaccine (adjuvanted RSVPreF3) offers protection to adul...
Public health impact and cost-effectiveness of the adjuvanted RSVPreF3 vaccine for respiratory syncytial virus prevention among adults aged 50 years and older in Germany [0.03%]
在德国50岁及以上成人中RSV预防性接种RSVPreF3疫苗的公共卫生影响及成本效益分析
Maria Waize,Pavo Marijic,Alen Marijam et al.
Maria Waize et al.
Background: Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract disease in older adults. Vaccination is effective against RSV disease and can reduce disease and economic burden. ...
Public health impact of adjuvanted RSVPreF3 vaccine in older adults: a modeling study in nine countries in Middle East and North Africa [0.03%]
一种加强型RSVPreF3疫苗对中东和北非九个国家老年人群的公共卫生影响：一项建模研究
Evelina Zimovetz,Abdullah M Assiri,Sara Al Dallal et al.
Evelina Zimovetz et al.
Background: The adjuvanted RSV prefusion F protein vaccine (adjuvanted RSVPreF3) can protect older adults against respiratory syncytial virus (RSV) infection and RSV-related lower respiratory track disease (LRTD). We mode...
Vaccination in adults at-increased risk of herpes zoster in Canada: insights from a multidisciplinary panel consensus [0.03%]
加拿大成人带状疱疹增加风险人群的疫苗接种：来自多学科小组共识的见解
Wayne Ghesquière,Dominique Tessier,Vivien Brown et al.
Wayne Ghesquière et al.
Background: Risk of herpes zoster (HZ) increases with age (notably at ≥50 years), with greater risk also apparent in immunocompromised populations. Use of recombinant zoster vaccine (RZV) in adults aged ≥50 years is est...
Broad-spectrum coronavirus vaccines: integrated strategies to combat viral diversity [0.03%]
广谱冠状病毒疫苗：应对病毒多样性的综合策略
Qian He,Yi Zhang,Zhihao Fu et al.
Qian He et al.
Introduction: The early 21st century witnessed three consecutive public health emergencies caused by Betacoronavirus infections, drawing considerable global attention on the hazards posed by Betacoronaviruses. Vaccines pr...
Real-world effectiveness of live attenuated influenza vaccines (LAIV) and inactivated influenza vaccines (IIV) in children from 2003 to 2023: a systematic literature review and network meta-analysis [0.03%]
2003至2023年儿童流感减毒活疫苗和灭活疫苗真实世界有效性的系统文献回顾与网状meta分析
Anke L Stuurman,Joshua Enxing,Aura V Gutiérrez et al.
Anke L Stuurman et al.
Introduction: Circulating influenza strains, vaccine effectiveness (VE), and vaccine recommendations vary over time. A systematic literature review (SLR), random effects meta-analysis (REMA), and network meta-analysis (NM...
The broader socio-economic value of adult respiratory disease vaccinations in the UK - results from a benefit cost analysis [0.03%]
在英国，成人呼吸道疾病疫苗的更广泛的社会经济价值——基于效益成本分析的结果
Cale Harrison,Simon Brassel,Sulayman Chowdhury et al.
Cale Harrison et al.
Background: Respiratory infections such as pneumococcal disease (PD), RSV, influenza (Flu), and COVID-19 impose a major socio-economic burden in the UK. Adult vaccination programs cost-effectively reduce this burden, yet ...
Impact of prior COVID-19 vaccination on major adverse kidney events in patients with non-dialysis dependent chronic kidney disease: a global retrospective study [0.03%]
新型冠状病毒疫苗对非透析慢性肾病患者不良肾脏事件的影响：一项全球回顾性研究
Chi-Ya Huang,Jheng-Yan Wu,Guan-Yu Lin et al.
Chi-Ya Huang et al.
Background: Vaccination prevents complications and death in patients with chronic kidney disease (CKD) and COVID-19, but concerns remain about post-vaccination kidney outcomes. This study assessed the real-world impact of...